Endosialin/CD248 may be a potential therapeutic target to prevent the invasion and metastasis in osteosarcoma

Kondo,Yumiko; Honoki,Kanya; Kishi,Shingo; Mori,Shiori; Fujiwara‑Tani,Rina; Tsukamoto,Shinji; Fujii,Hiromasa; Kuniyasu,Hiroki; Tanaka,Yasuhito

doi:10.3892/ol.2021.13160

Endosialin/CD248 may be a potential therapeutic target to prevent the invasion and metastasis in osteosarcoma

Authors:
- Yumiko Kondo
- Kanya Honoki
- Shingo Kishi
- Shiori Mori
- Rina Fujiwara‑Tani
- Shinji Tsukamoto
- Hiromasa Fujii
- Hiroki Kuniyasu
- Yasuhito Tanaka
View Affiliations

Affiliations: Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara 634‑8521, Japan, Department of Molecular Pathology, Nara Medical University, Kashihara, Nara 634‑8521, Japan
Published online on: December 6, 2021 https://doi.org/10.3892/ol.2021.13160
Article Number: 42
Copyright: © Kondo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endosialin/CD248/tumor endothelial marker 1 is classified as a C‑type lectin‑like transmembrane receptor, found on the plasma membrane of activated mesenchymal cells, which binds to fibronectin. Although endosialin is expressed at high levels in stem‑like cells of sarcomas, its role has not been fully uncovered. The present study aimed to determine whether endosialin expression is associated with tumor progression and metastasis, and whether endosialin has the potential to act as a novel therapeutic target in osteosarcoma (OS) using MORAb‑004/ontuxizumab, a humanized monoclonal antibody, which targets the type C lectin domain of endosialin. The results demonstrated that endosialin was highly expressed in OSs with metastatic disease. Furthermore, MORAb‑004 had no cytostatic effect on OS cells in vitro and did not change the expression of stem cells and differentiation markers; however, it inhibited migration of OS cells. Taken together, these results suggest that endosialin may play a role in migration, and may be involved in the metastatic process of OSs. Furthermore, MORAb‑004 reduces the motility of OS cells, and suppresses invasion and the development of metastatic lesions.

View Figures

View References

1	Teicher BA: CD248: A therapeutic target in cancer and fibrotic diseases. Oncotarget. 10:993–1009. 2019. View Article : Google Scholar : PubMed/NCBI
2	Christian S, Ahorn H, Koehler A, Eisenhaber F, Rodi H-P, Garin-Chesa P, Park JE, Rettig WJ and Lenter MC: Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem. 276:7408–7414. 2001. View Article : Google Scholar : PubMed/NCBI
3	Viski C, König C, Kijewska M, Mogler C, Isacke CM and Augustin HG: Endosialin-Expressing Pericytes Promote Metastatic Dissemination. Cancer Res. 76:5313–5325. 2016. View Article : Google Scholar : PubMed/NCBI
4	Tomkowicz B, Rybinski K, Foley B, Ebel W, Kline B, Routhier E, Sass P, Nicolaides NC, Grasso L and Zhou Y: Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci USA. 104:17965–17970. 2007. View Article : Google Scholar : PubMed/NCBI
5	Sun D-X, Liao G-J, Liu K-G and Jian H: Endosialin expressing bone sarcoma stem like cells are highly tumor initiating and invasive. Mol Med Rep. 12:5665–5670. 2015. View Article : Google Scholar : PubMed/NCBI
6	Lange SE, Zheleznyak A, Studer M, O'Shannessy DJ, Lapi SE and Van Tine BA: Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications. Oncotarget. 7:13082–13092. 2016. View Article : Google Scholar : PubMed/NCBI
7	Rybinski K, Imtiyaz HZ, Mittica B, Drozdowski B, Fulmer J, Furuuchi K, Fernando S, Henry M, Chao Q, Kline B, et al: Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 6:25429–25440. 2015. View Article : Google Scholar : PubMed/NCBI
8	Diaz LA Jr, Coughlin CM, Weil SC, Fishel J, Gounder MM, Lawrence S, Azad N, O'Shannessy DJ, Grasso L, Wustner J, et al: A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clin Cancer Res. 21:1281–1288. 2015. View Article : Google Scholar : PubMed/NCBI
9	Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, et al: A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 125:2445–2454. 2019. View Article : Google Scholar : PubMed/NCBI
10	Kuniyasu H, Yasui W, Shinohara H, Yano S, Ellis LM, Wilson MR, Bucana CD, Rikita T, Tahara E and Fidler IJ: Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. Am J Pathol. 157:1523–1535. 2000. View Article : Google Scholar : PubMed/NCBI
11	Bagley RG, Rouleau C, St Martin T, Boutin P, Weber W, Ruzek M, Honma N, Nacht M, Shankara S, Kataoka S, et al: Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248. Mol Cancer Ther. 7:2536–2546. 2008. View Article : Google Scholar : PubMed/NCBI
12	Schneider CA, Rasband WS and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
13	Tanabe E, Kitayoshi M, Fujii K, Ohmori H, Luo Y, Kadochi Y, Mori S, Fujiwara R, Nishiguchi Y, Sasaki T, et al: Fatty acids inhibit anticancer effects of 5-fluorouracil in mouse cancer cell lines. Oncol Lett. 14:681–686. 2017. View Article : Google Scholar : PubMed/NCBI
14	Li L, Qiu RL, Lin Y, Cai Y, Bian Y, Fan Y and Gao XJ: Resveratrol suppresses human cervical carcinoma cell proliferation and elevates apoptosis via the mitochondrial and p53 signaling pathways. Oncol Lett. 15:9845–9851. 2018.PubMed/NCBI
15	Kishi S, Fujiwara-Tani R, Luo Y, Kawahara I, Goto K, Fujii K, Ohmori H, Nakashima C, Sasaki T and Kuniyasu H: Pro-metastatic signaling of the trans fatty acid elaidic acid is associated with lipid rafts. Oncol Lett. 15:4423–4426. 2018.PubMed/NCBI
16	Luo Y, Fujii K, Ohmori H, Sasahira T, Moriwaka Y, Isobe M and Kuniyasu H: Antisense phosphorothioate oligodeoxynucleic acid for CD10 suppresses liver metastasis of colorectal cancer. Pathobiology. 76:267–273. 2009. View Article : Google Scholar : PubMed/NCBI
17	van der Meer AD, Vermeul K, Poot AA, Feijen J and Vermes I: A microfluidic wound-healing assay for quantifying endothelial cell migration. Am J Physiol Heart Circ Physiol. 298:H719–H725. 2010. View Article : Google Scholar : PubMed/NCBI
18	Suarez-Arnedo A, Torres Figueroa F, Clavijo C, Arbeláez P, Cruz JC and Muñoz-Camargo C: An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. PLoS One. 15:e02325652020. View Article : Google Scholar : PubMed/NCBI
19	Lindsey BA, Markel JE and Kleinerman ES: Osteosarcoma Overview. Rheumatol Ther. 4:25–43. 2017. View Article : Google Scholar : PubMed/NCBI
20	Broadhead ML, Clark JCM, Myers DE, Dass CR and Choong PFM: The molecular pathogenesis of osteosarcoma: A review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
21	Nanda A, Karim B, Peng Z, Liu G, Qiu W, Gan C, Vogelstein B, St Croix B, Kinzler KW and Huso DL: Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci USA. 103:3351–3356. 2006. View Article : Google Scholar : PubMed/NCBI
22	Tomkowicz B, Rybinski K, Sebeck D, Sass P, Nicolaides NC, Grasso L and Zhou Y: Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling. Cancer Biol Ther. 9:908–915. 2010. View Article : Google Scholar : PubMed/NCBI